AI and regulatory complexity are driving demand for life sciences software, attracting private equity firms such as Ardian, Bregal Sagemount, Eir Partners, and Thoma Bravo. These tailwinds and investments are discussed in an eight-deal listicle.

1315 Capital closed a carve-out deal with a portfolio company of Telegraph Hill Partners and New Vale Capital, focusing on the manufacturing subsegment. Harrison Brunelli, principal at Bregal Sagemount, said AI across pharmaceutical research and regulatory workflows creates significant investment opportunities.

In September, Eir Partners acquired Accumulus Technologies, a cloud-based platform for regulatory collaboration. Operating out of San Francisco, Accumulus was spun out in 2025 and has more than 75 regulatory authorities connected. Brett Carlson, founder and CEO of Eir Partners, called it a compelling partnership.

In August, Thoma Bravo completed the take-private of Kneat Solutions for $466 million, a 40% premium. The Limerick, Ireland-based company's Kneat Gx platform digitalizes data for integrity and traceability.